Letícia Conceição Braga

Dr. Letícia Conceição Braga

Translation Oncology Reseach Lab, Instituto Mario Penna, Belo Horizonte, Minas Gerais, Brazil
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 January 2019 in JBRA Assisted Reproduction
Verified
Journal Article
Open access
RBRenata de Lima Bossi
Renata de Lima Bossi
JVJéssica Bruna Fernandes Valadares
Jéssica Bruna Fernandes Valadares
HPHelen Lima Del Puerto
Helen Lima Del Puerto
MRMaria Gabrielle Lima Rocha
Maria Gabrielle Lima Rocha
Letícia Conceição BragaLetícia Conceição Braga
Letícia Conceição Braga
SGSelmo Geber
Selmo Geber
The aim of our study was to identify the prevalence of HPV in the semen of men submitted to ART treatment and look into the possible impacts of the virus on sperm parameters. Thirty-five patients treated for infertility from March to August 2016 were invited to join the study. Samples with a minimum concentration of 40x106 spermatozoa per milliliter were included in the study. After the evaluation of semen parameters, DNA extraction and PCR were performed to verify the presence of HPV by electrophoresis in 8% polyacrylamide gel. Patient age ranged from 27 to 68 years (mean 39.2 years). Semen analysis showed a mean volume of 2.5mL; mean concentration of 58.9x106; and mean motility of 51.8%. HPV DNA was identified in seven semen samples from 25 patients (28%). Ten samples with DNA concentrations below 10ng/µL were excluded from the study due to poor amplification quality. There was no statistical difference in sperm concentration when HPV-negative and HPV-positive samples were compared (65.9x106 vs. 62.3x106; p=0.70). However, sperm motility was significantly higher in HPV-positive semen (65% vs. 46.6%; p=0.02). HPV prevalence was 28% in the semen of patients submitted to ART treatment. HPV-positive samples had statistically increased motility compared to negative samples (65% vs. 46.6%; p=0.02).

1 February 2023 in Revista Brasileira de Ginecologia e Obstetrícia
Verified
Journal Article
Open access
PDF file
CCCamila Martins de Carvalho
Camila Martins de Carvalho
Letícia Conceição BragaLetícia Conceição Braga
Letícia Conceição Braga
LSLuciana Maria Silva
Luciana Maria Silva
ACAnisse Marques Chami
Anisse Marques Chami
ASAgnaldo Silva-Filho
Agnaldo Silva-Filho
Objective The present study evaluated the profile of germline mutations present in patients who underwent genetic counseling for risk assessment for breast cancer (BC), ovarian cancer (OC), and endometrial cancer (EC) with a possible hereditary pattern. Methods Medical records of 382 patients who underwent genetic counseling after signing an informed consent form were analyzed. A total of 55.76% of patients (213/382) were symptomatic (personal history of cancer), and 44.24% (169/382) were asymptomatic (absence of the disease). The variables analyzed were age, sex, place of birth, personal or family history of BC, OC, EC, as well as other types of cancer associated with hereditary syndromes. The Human Genome Variation Society (HGVS) nomenclature guidelines were used to name the variants, and their biological significance was determined by comparing 11 databases. Results We identified 53 distinct mutations: 29 pathogenic variants, 13 variants of undetermined significance (VUS), and 11 benign. The most frequent mutations were BRCA1 c.470_471delCT, BRCA1 c.4675 + 1G > T, and BRCA2 c.2T> G. Furthermore, 21 variants appear to have been described for the first time in Brazil. In addition to BRCA1/2 mutations, variants in other genes related to hereditary syndromes that predispose to gynecological cancers were found. Conclusion This study allowed a deeper understanding of the main mutations identified in families in the state of Minas Gerais and demonstrates the need to assess the family history of non-gynecological cancer for risk assessment of BC, OC, and EC. Moreover, it is an effort that contributes to population studies to evaluate the cancer risk mutation profile in Brazil.

1 January 2020 in Clinics
Verified
Journal Article
Open access
Letícia Conceição BragaLetícia Conceição Braga
Letícia Conceição Braga
NGNikole Gontijo Gonçales
Nikole Gontijo Gonçales
RFRafaela de Souza Furtado
Rafaela de Souza Furtado
WAWarne Pedro de Andrade
Warne Pedro de Andrade
LSLuciana Maria Silva
Luciana Maria Silva
ASAgnaldo Silva-Filho
Agnaldo Silva-Filho
The objectives of this study were to determine the sensitivity of ovarian cancer (OC) cell lines (TOV-21G and SKOV-3) to cisplatin and to the recombinant human TRAIL (rhTRAIL), and to evaluate the expression profile of TNFRSF10B, TNFRSF10C, TP53TG5, MDM2, ...

15 July 2025 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
ALAline Brito de Lima
Aline Brito de Lima
BGBryan Ôrtero Perez Gonçalves
Bryan Ôrtero Perez Gonçalves
MMMilene Pereira Moreira
Milene Pereira Moreira
BBBárbara Avelar Ferreira Barros
Bárbara Avelar Ferreira Barros
AFAgnaldo Lopes da Silva Filho
Agnaldo Lopes da Silva Filho
LSLuciana Maria Silva
Luciana Maria Silva

25 August 2020 in Oncology Letters
Verified
Journal Article
Open access
PDF file
BGBryan Ôrtero Perez Gonçalves
Bryan Ôrtero Perez Gonçalves
WAWarne Pedro de Andrade
Warne Pedro de Andrade
Letícia Conceição BragaLetícia Conceição Braga
Letícia Conceição Braga
SFSílvia Ligório Fialho
Sílvia Ligório Fialho
LSLuciana Maria Silva
Luciana Maria Silva
The epithelial‑to‑mesenchymal transition (EMT) is a phenomenon during which cancer epithelial cells undergo changes in plasticity and lose cell‑cell adhesion with consequent remodeling of the extracellular matrix and development of mesenchymal characteristics. Long non‑coding RNAs (lncRNAs) have been described as EMT modulation markers, becoming a promising target in the development of new therapies for cancer. The present study aimed to investigate the role of everolimus at 100 nM as inductor of the EMT phenomenon in cell lines derived from human breast (BT‑549), colorectal (RKO‑AS45‑1) and ovary (TOV‑21G) cancer. The integrity of cellular junctions was monitored using an in vitro model of epithelial resistance. The results demonstrated that the EMT genes ZEB1, TWIST1 and TGFB1 were differentially expressed in cells treated with everolimus compared with in untreated cells. lncRNA HOTAIR was upregulated post‑­treatment only in BT‑549 cells compared with in untreated cells. After treatment with everolimus, the intensity of fluorescence of P‑cadherin decreased, and that of fibronectin increased in RKO‑AS45‑1 and TOV‑21G cells compared with control cells. The transepithelial electrical resistance at the RKO‑AS45‑1 monolayer treated with everolimus started to decrease at 48 h. The changes in the gene expression and epithelial resistance may confirm the role of everolimus in EMT.